PL3129374T3 - (5,6-Dihydro)pirymido[4,5-e]indolizyny - Google Patents

(5,6-Dihydro)pirymido[4,5-e]indolizyny

Info

Publication number
PL3129374T3
PL3129374T3 PL15712912T PL15712912T PL3129374T3 PL 3129374 T3 PL3129374 T3 PL 3129374T3 PL 15712912 T PL15712912 T PL 15712912T PL 15712912 T PL15712912 T PL 15712912T PL 3129374 T3 PL3129374 T3 PL 3129374T3
Authority
PL
Poland
Prior art keywords
indolizines
pyrimido
dihydro
Prior art date
Application number
PL15712912T
Other languages
English (en)
Polish (pl)
Inventor
Adrianus Petrus Antonius De Man
Rogier Christian Buijsman
Jan Gerard STERRENBURG
Joost Cornelis Marinus UITDEHAAG
Joeri Johannes Petrus DE WIT
Guido Jenny Rudolf Zaman
Original Assignee
Netherlands Translational Research Center B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Research Center B.V. filed Critical Netherlands Translational Research Center B.V.
Publication of PL3129374T3 publication Critical patent/PL3129374T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15712912T 2014-04-07 2015-03-30 (5,6-Dihydro)pirymido[4,5-e]indolizyny PL3129374T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines
EP15712912.3A EP3129374B1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (1)

Publication Number Publication Date
PL3129374T3 true PL3129374T3 (pl) 2019-07-31

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15712912T PL3129374T3 (pl) 2014-04-07 2015-03-30 (5,6-Dihydro)pirymido[4,5-e]indolizyny

Country Status (16)

Country Link
US (3) US9856258B2 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3129374T3 (en) * 2014-04-07 2019-04-08 Netherlands Translational Res Center B V (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
JP6912486B2 (ja) * 2016-02-19 2021-08-04 フェニックス モレキュラー デザインズ Rsk阻害剤として有用なカルボキサミド誘導体
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
WO2018172984A1 (en) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
KR20210126077A (ko) 2019-02-11 2021-10-19 피닉스 몰레큘라 디자인스 Rsk 억제제의 결정형
MX2024007450A (es) * 2021-12-15 2024-07-04 Sillajen Inc Combinaciones farmaceuticas para utilizarse en el tratamiento de enfermedades neoplasicas.
AU2022408915B2 (en) * 2021-12-15 2026-05-14 Sillajen, Inc. Methods of treating neoplastic diseases
KR20240096905A (ko) * 2021-12-15 2024-06-26 신라젠(주) 변형된 베타-사이클로덱스트린을 포함하는 약제학적 조성물
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
EA010904B1 (ru) 2003-05-22 2008-12-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
US8207180B2 (en) 2006-11-28 2012-06-26 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
AU2009264431B2 (en) * 2008-06-26 2013-11-07 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
CN102470136B (zh) 2009-07-29 2013-12-25 内尔维阿诺医学科学有限公司 Plk 抑制剂的盐类
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
RU2591191C2 (ru) * 2011-01-26 2016-07-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы
EP3013823B1 (en) 2013-06-24 2017-11-01 Merck Patent GmbH Imidazole compounds as modulators of fshr and uses thereof
DK3129374T3 (en) * 2014-04-07 2019-04-08 Netherlands Translational Res Center B V (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER

Also Published As

Publication number Publication date
EP3129374B1 (en) 2018-12-19
MX2016012997A (es) 2016-12-07
KR20170013866A (ko) 2017-02-07
CA2944610C (en) 2024-01-09
WO2015155042A1 (en) 2015-10-15
CN106132963A (zh) 2016-11-16
USRE48974E1 (en) 2022-03-15
DK3129374T3 (en) 2019-04-08
BR112016022342A8 (pt) 2021-07-20
RU2016141405A (ru) 2018-05-07
HUE043108T2 (hu) 2019-07-29
AU2015243694B2 (en) 2019-01-17
USRE50082E1 (en) 2024-08-20
US20170096432A1 (en) 2017-04-06
KR102432420B1 (ko) 2022-08-17
ES2716165T3 (es) 2019-06-10
US9856258B2 (en) 2018-01-02
RU2016141405A3 (enExample) 2018-10-02
PT3129374T (pt) 2019-03-25
CA2944610A1 (en) 2015-10-15
AU2015243694A1 (en) 2016-11-03
CN106132963B (zh) 2019-08-06
JP2017510595A (ja) 2017-04-13
JP6518690B2 (ja) 2019-05-22
MX368767B (es) 2019-10-15
EP3129374A1 (en) 2017-02-15
BR112016022342A2 (pt) 2017-08-15
BR112016022342B1 (pt) 2022-10-04
RU2692479C2 (ru) 2019-06-25

Similar Documents

Publication Publication Date Title
HUE043108T2 (hu) (5,6-dihidro)pirimido[4,5-e]indolizinek
IL259169A (en) Novel pyrazolo pyrimidine derivatives
ZA201705802B (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
DK3134403T3 (en) 1h-pyrrolo[2,3-c]pyridin-7(6h)-on og pyrazolo[3,4-c]pyridin-7(6h)-on som inhibitorer af bet-proteiner
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
IL250823A0 (en) A new derivative of 6,5-dihydro-h4-benzo[b]thiano-[3,2-d]azepine
IL254167A0 (en) Combinations containing modified 3,2-dihydroimidazo[2,1-c]quinazoline
IL243092A0 (en) New triazolo[d–4,5]pyrimidine histories
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
HUE038764T2 (hu) 2,7-Diazaspiro[3.5]nonán vegyületek
ZA201804619B (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
EP3272627A4 (en) Multi-purpose vehicle
EP3190111A4 (en) Pyrazolo[3,4-c]pyridine derivatives
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
IL250350A0 (en) History of tetrahydropyrrolo[4,3–][d3,1]thiazine as a BACE inhibitor
EP3227292A4 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
GB2553716B (en) Pyrrolopyrimidines as antitumor agents
HK1240222A1 (en) 4h-pyrido[1,2-a]pyrimidin-4-one compounds
AU2014904868A0 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
ZA201801639B (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่